Browsing Tag
Tango Therapeutics
3 posts
Erasca (NASDAQ: ERAS) climbs into ASCO 2026 as pan-RAS thesis gets second wind
Erasca lost half its value on an IP challenge and a trial death. Now ASCO 2026 looms, Merck is on board, and traders are positioning before the verdict.
Tango Therapeutics (NASDAQ: TNGX) jumps 11% into May 11 earnings and pivotal pancreatic cancer data
Tango Therapeutics is up 22-fold from $1.04 in twelve months. The May 11 earnings print decides whether vopimetostat justifies the run or breaks it.
Tango Therapeutics raises $225m in equity offering and PIPE to fuel precision oncology pipeline
Find out how Tango Therapeutics’ $225 M equity and PIPE financing could reshape its precision-oncology strategy and investor sentiment.